Following white papers in September 2015 and February 2016, here Boehringer Ingelheim UK provides an update on its patient centricity initiative ahead of a new white paper later this year.

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Boehringer Ingelheim’s sustainability strategy addresses health equity and wellbeing across the whole patient continuum of care: from pharmaceutical innovation over prevention and healthcare delivery ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Boehringer Ingelheim’s Ulrike Graefe-Mody on her career path; Driving launch excellence; Top trends coming out of ESMO 2024 ...

"Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients," said Anthony Costello, chief executive of Medidata's Patient Cloud unit. "Together, we will be ...

They also found patient selection for endovascular therapy ... participation in an advisory board for Alexion/Portola, Boehringer Ingelheim, Biogen, and Acthera; is a member of a clinical event ...